A single-center experience of 1500 lung transplant patients

Slides:

Advertisements

Similar presentations

The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;

Advertisements

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Two decades of pediatric lung transplant in the United States: Have we improved? Farhan Zafar, MD, Jeffrey S. Heinle, MD, Marc G. Schecter, MD, Joseph.

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease Joseph E. Bavaria, MD, Alberto Pochettino,

Lobar lung transplantation: One size fits all

Mitral stenosis with pulmonary hypertension: We should operate early

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Does the method of lung preservation influence outcome after transplantation? An analysis of 681 consecutive procedures J. Saravana Ganesh, FRCS, Chris.

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

The effect of center volume on the incidence of postoperative complications and their impact on survival after lung transplantation Arman Kilic, MD,

Lung transplantation with donation after cardiac death donors: Long-term follow-up in a single center Nilto C. De Oliveira, MD, Satoru Osaki, MD, PhD,

Does the Presence of Preoperative Mild or Moderate Coronary Artery Disease Affect the Outcomes of Lung Transplantation? Cliff K. Choong, FRACS, Bryan.

David P. Mason, MD, Jeevanantham Rajeswaran, MS, Sudish C

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Extended pericardiotomy avoids cardiopulmonary bypass during bilateral sequential lung transplantation Takahiro Oto, MD, Marc Rabinov, FRACS, Franklin.

Thirteen-year experience in lung transplantation for emphysema

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Benefits of resection for metachronous lung cancer

Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases Felix G. Fernandez, MD, Benjamin D. Kozower,

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Prospective evaluation of patients readmitted after cardiac surgery: Analysis of outcomes and identification of risk factors Hersh S. Maniar, MD, Jennifer.

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Abbas Emaminia, MD, Sara A

Tara R. Semenkovich, MD, MPHS, Christine Frederiksen, MS, Jessica L

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Jason M. Gauthier, MD, Andrew J

David P. Mason, MD, Lillian H. Batizy, MS, Jeffrey Wu, MD, Edward R

The impact of smoking in primary spontaneous pneumothorax

Treatment Outcomes in Stage I Lung Cancer

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Comparative study of bronchial artery revascularization in lung transplantation Gösta B. Pettersson, MD, PhD, Karam Karam, MD, Lucy Thuita, MS, Douglas.

Yinin Hu, MD, Varun Puri, MD, Traves D

Do we need a bibliometrician to know which way the wind is blowing?

A first start for lung transplantation?

The influence of retransplantation on survival for pediatric lung transplant recipients Ryuichi Waseda, MD, PhD, Alberto Benazzo, MD, Konrad Hoetzenecker,

Third-time lung transplantation in a patient with cystic fibrosis

Open thoracoabdominal aortic repair for chronic type B dissection

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Daniel Kreisel, MD, PhD, Alexander S

Long-term survival in lung transplant recipients after successful preoperative coronary revascularization Leonardo Seoane, MD, Lee M. Arcement, MD, Vincent.

A fate worse than death Jennifer S. Lawton, MD

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Outcome of bilateral lung volume reduction in patients with emphysema potentially eligible for lung transplantation Bryan F. Meyers, MD, Roger D. Yusen,

Taking UP the chronic pulmonary obstructive disease gauntlet

The ascent of POEM: Double-tunnel per oral endoscopic re-myotomy

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Syphilitic aortitis: The bigger picture

Siva Raja, MD, PhD, Jay J. Idrees, MD, Eugene H

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Surveillance and the second primary lung cancer: Enhancing our understanding beyond Martini and Melamed Melanie P. Subramanian, MD, Varun Puri, MD, MSCI

The future of cardiac surgery training: A survival guide

Antibodies to Self-Antigens Predispose to Primary Lung Allograft Dysfunction and Chronic Rejection Ankit Bharat, MD, Deepti Saini, PhD, Nancy Steward,

The Robin Hood principle in the treatment of congenital heart disease: Taking technologic developments intended for adults and using it in kids Paul.

“The more things change…”: The challenges ahead

Apples remain apples NO matter what

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Kalpaj Parekh, MD, Bryan F. Meyers, MD, G

Lessons learned from Melody valve retrieved at transplantation

Commentary: Evaluation of primary graft dysfunction after lung transplantation—It is time to teach an old dog new tricks! W. Hampton Gray, MD, P. Michael.

Definitions of primary graft dysfunction after lung transplantation: Differences between bilateral and single lung transplantation Takahiro Oto, MD,

Presentation transcript:

A single-center experience of 1500 lung transplant patients Keki R. Balsara, MD, Alexander S. Krupnick, MD, Jennifer M. Bell, RN, Ali Khiabani, MD, Masina Scavuzzo, RN, BSN, Ramsey Hachem, MD, Elbert Trulock, MD, Chad Witt, MD, Derek E. Byers, MD, PhD, Roger Yusen, MD, Bryan Meyers, MD, MPH, Benjamin Kozower, MD, G. Alexander Patterson, MD, Varun Puri, MD, MSCI, Daniel Kreisel, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 156, Issue 2, Pages 894-905.e3 (August 2018) DOI: 10.1016/j.jtcvs.2018.03.112 Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Overall survival of all 1500 transplanted patients as a function of time. Ninety-five percent confidence limits are represented by the thin lines. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Overall survival stratified by diagnosis groups, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (IPF), and other (including pulmonary hypertension, α-1 anti-trypsin deficiency, and lymphangioleiomyomastosis). There is a statistically significant difference in survival among the groups (P < .007). Ninety-five percent confidence limits are represented by the thin lines. See Table E1 for survival and 95% confidence intervals separated by disease process. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Overall survival stratified by time groups. Early transplant (group 1) had decreased short- and long-term survival when compared with late transplant (group 2; P < .0001). Ninety-five percent confidence limits are represented by the thin lines. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 A, Overall survival stratified by diagnosis groups in early transplant patients. Ninety-five percent confidence limits are represented by the thin lines. See Table E2 for survival and 95% confidence intervals separated by disease process. B, Overall survival stratified by diagnosis groups in late transplant patients. Ninety-five percent 95% confidence limits are represented by the thin lines. See Table E3 for survival and 95% confidence intervals separated by disease process. CF, Cystic fibrosis; COPD, chronic obstructive pulmonary disease; IPF, interstitial pulmonary fibrosis. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 A, Overall time to development of bronchiolitis obliterans syndrome (BOS). Ninety-five percent confidence limits are represented by the thin lines. B, Overall time to development of BOS, stratified by time groups. Early transplant (group 1) had a statistically significant reduced freedom from BOS at all time points compared to late transplant (group 2; P < .0001). Ninety-five percent confidence limits are represented by the thin lines. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Freedom from bronchiolitis obliterans syndrome (BOS) for patients with chronic obstructive pulmonary disease, separated by group. Early transplant (pre-las) and late transplant (post-las) 95% confidence limits are represented by the thin lines. COPD, Chronic obstructive pulmonary disease. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure E2 Freedom from bronchiolitis obliterans syndrome (BOS) for patients with cystic fibrosis, separated by group. Early transplant (pre-las) and late transplant (post-las) 95% confidence limits are represented by the thin lines. CF, Cystic fibrosis. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure E3 Freedom from bronchiolitis obliterans syndrome (BOS) for patients with interstitial pulmonary fibrosis, separated by group. Early transplant (pre-las) and late transplant (post-las) 95% confidence limits are represented by the thin lines. PF, Pulmonary fibrosis. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Overall survival of all patients separated by disease process. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Video 1 Video recording highlighting the most salient features of this manuscript using slides from The American Association for Thoracic Surgery 2017 oral presentation. Information highlighted includes overall survival, disease-specific survival, and incidence of primary graft dysfunction and bronchiolitis obliterans syndrome across all groups examined. Video available at: https://www.jtcvs.org/article/S0022-5223(18)30894-8/fulltext. The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905 The Journal of Thoracic and Cardiovascular Surgery 2018 156, 894-905.e3DOI: (10.1016/j.jtcvs.2018.03.112) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions